Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma von Davies, Faith E, Rosenthal, Adam, Rasche, Leo, Petty, Nathan M, McDonald, James E, Ntambi, James A, Steward, Doug M, Panozzo, Susan B, van Rhee, Frits, Zangari, Maurizio, Schinke, Carolina D, Thanendrarajan, Sharmilan, Walker, Brian, Weinhold, Niels, Barlogie, Bart, Hoering, Antje, Morgan, Gareth J

Volltext

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma von Boyle, Eileen M., Ashby, Cody, Tytarenko, Ruslana G., Deshpande, Shayu, Wang, Hongwei, Wang, Yan, Rosenthal, Adam, Sawyer, Jeffrey, Tian, Erming, Flynt, Erin, Hoering, Antje, Johnson, Sarah K., Rutherford, Michael W., Wardell, Christopher P., Bauer, Michael A., Dumontet, Charles, Facon, Thierry, Thanendrarajan, Sharmilan, Schinke, Carolina D., Zangari, Maurizio, van Rhee, Frits, Barlogie, Bart, Cairns, David, Jackson, Graham, Thakurta, Anjan, Davies, Faith E., Morgan, Gareth J., Walker, Brian A.

Volltext

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias von Sridharan, Ashwin, Schinke, Carolina D., Georgiev, George, Da Silva Ferreira, Mariana, Thiruthuvanathan, Victor, MacArthur, Ian, Bhagat, Tushar D., Choudhary, Gaurav S., Aluri, Srinivas, Chen, Jiahao, Pradhan, Kith, Xia, Yu, Panjikaran, Maya, Sims, Gregory, Bhagat, Chirag K., Bender, Ryan, Keeler, Lauryn, Graber, Armin, Heuck, Christoph, Fletcher, Frederick A., Alapat, Daisy, Weinhold, Niels, Johnson, Sarah K., Wickrema, Amittha, Barlogie, Bart, Morgan, Gareth J., Shastri, Aditi, Steidl, Ulrich, Will, Britta, Verma, Amit

Volltext

Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA von Deshpande, Shayu, Tytarenko, Ruslana G., Wang, Yan, Boyle, Eileen M., Ashby, Cody, Schinke, Carolina D., Thanendrarajan, Sharmilan, Zangari, Maurizio, Zhan, Fenghuang, Davies, Faith E., Morgan, Gareth J., van Rhee, Frits, Walker, Brian A.

Volltext

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome von Sawyer, Jeffrey R., Tian, Erming, Walker, Brian A., Wardell, Christopher, Lukacs, Janet L., Sammartino, Gael, Bailey, Clyde, Schinke, Carolina D., Thanendrarajan, Sharmilan, Davies, Faith E., Morgan, Gareth J., Barlogie, Bart, Zangari, Maurizio, van Rhee, Frits

Volltext

Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up von Al Hadidi, Samer, Ababneh, Obada Ehab, Schinke, Carolina D., Thanendrarajan, Sharmilan, Bailey, Clyde, Smith, Robert, Panozzo, Susan, Alapat, Daisy, Cottler-Fox, Michele, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang, Sawyer, Jeffrey, Barlogie, Bart, Zangari, Maurizio, van Rhee, Frits

Volltext

PHF19 inhibition as a therapeutic target in multiple myeloma von Schinke, Carolina D., Bird, Jordan T., Qu, Pingping, Yaccoby, Shmuel, Lyzogubov, Valeriy V., Shelton, Randal, Ling, Wen, Boyle, Eileen M., Deshpande, Sharyu, Byrum, Stephanie D., Washam, Charity, Mackintosh, Samuel, Stephens, Owen, Thanendrarajan, Sharmilan, Zangari, Maurizio, Shaughnessy, John, Zhan, Fenghuang, Barlogie, Bart, van Rhee, Frits, Walker, Brian A

Volltext

RITUXIMAB AND CARDIOTOXICIY von Rabinovitz, Asaf, Lombardo, Marissa, Schinke, Carolina D, Wang, Dan, Abdissa, Negassa, Garcia, Mario

Volltext

Gender disparities in multiple myeloma publications von Dweik, Aala, Dweik, Hadeel, Mian, Hira, Mohan, Meera, Schinke, Carolina D., Al Hadidi, Samer

Volltext

Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB von Al Hadidi, Samer, Ababneh, Obada Ehab, Schinke, Carolina D., Thanendrarajan, Sharmilan, Bailey, Clyde, Zangari, Maurizio, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang, Sawyer, Jeffrey, Barlogie, Bart, van Rhee, Frits

Volltext

Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols von Al Hadidi, Samer, Ababneh, Obada Ehab, Schinke, Carolina D., Thanendrarajan, Sharmilan, Bailey, Clyde, Zangari, Maurizio, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang, Sawyer, Jeffrey, van Rhee, Frits, Barlogie, Bart

Volltext

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome von Mohan, Meera, Kendrick, Samantha, Pandey, Yadav, Parikh, Richa, Farmer, Phil, Kottarathara, Mathew, Hoque, Shadiqul, Mitma, Angel, Thanendrarajan, Sharmilan, Schinke, Carolina D., Tricot, Guido, Zangari, Maurizio, van Rhee, Frits

Volltext

Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTA... von Rodríguez-Otero, Paula, Schinke, Carolina D., Chari, Ajai, Lipe, Brea, Lavi, Noa, Rasche, Leo, Vishwamitra, Deeksha, Skerget, Sheri, Verona, Raluca, Ma, Xuewen, Khedkar, Sheetal, Hilder, Brandi, Masterson, Tara J., Campagna, Michela, Renaud, Thomas, Tolbert, Jaszianne A., Heuck, Christoph, Smit, Marie-Anne Damiette, van de Donk, Niels W.C.J.

Volltext

Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM) von Janardan, Abhishek, Lindsay, Hammons, Szabo, Aniko, Bhatlapenumarthi, Vineel, Annyapu, Evanka, Dhakal, Binod, Narra, Ravi Kishore, Al Hadidi, Samer, Venniyil Radhakrishnan, Sabarinath, Bhutani, Divaya, Thanendrarajan, Sharmilan, Siegfried, Janz, Zangari, Maurizio, Lentzsch, Suzanne, van Rhee, Frits, D'Souza, Anita, Chakraborty, Rajshekhar, Schinke, Carolina D., Mohan, Meera

Volltext

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM) von Schinke, Carolina D., Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, Maria-Victoria, Rasche, Leo, Ye, Jing Christine, Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Campagna, Michela, Masterson, Tara J., Hilder, Brandi, Tolbert, Jaszianne A., Renaud, Thomas, Goldberg, Jenna, Heuck, Christoph, Chari, Ajai

Volltext

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells von Tian, Erming, Sawyer, Jeffery R., Edmondson, Ricky D., Zangari, Maurizio, Wardell, Christopher P., Thanendrarajan, Sharmilan, Schinke, Carolina D., van Rhee, Frits

Volltext

Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM) von Yarlagadda, Lakshmi, Gundarlapalli, Sravani, Parikh, Richa, Kottarathara, Mathew, Ogunsesan, Yetunde, Hoque, Shadiqul, Mitma, Angel, Bailey, Clyde, Hill, Kerri, Thanendrarajan, Sharmilan, Grazziutti, Monica, Mohan, Meera, Zangari, Maurizio, Van Rhee, Frits, Tricot, Guido, Schinke, Carolina D.

Volltext

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells von Mehdi, Syed J., Johnson, Sarah K, Garg, Tarun K., Ashby, Cody, Zangari, Maurizio, Schinke, Carolina D., Thanendrarajan, Sharmilan, Epstein, Joshua, Walker, Brian A, van Rhee, Frits, Yaccoby, Shmuel

Volltext

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission von Larsen, Kristin, Mohan, Meera, Bailey, Clyde, Hill, Kerri, Spencer, Horace, Kottarathara, Mathew, Parikh, Richa, Hoque, Shadiqul, Erra, Amani, Mitma, Angel, Mathur, Pankaj, Tricot, Guido, Thanendrarajan, Sharmilan, Zangari, Maurizio, van Rhee, Frits, Schinke, Carolina D.

Volltext

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma von Tan, Xuelian, Ashby, Timothy Cody, Zhu, Yuqi, Li, Can, Shen, Xuxing, Brockman, Qierra, Gai, Dongzheng, Johnson, Sarah K, Yong, Donghoon, Schinke, Carolina D., Zangari, Maurizio, van Rhee, Frits, Shaughnessy, John, Huang, Dingming, Frech, Ivana, Tricot, Guido J., Zhan, Fenghuang

Volltext